February 24th, 2007
Gene Profiling Predicts Resistance to Breast Cancer Drug Herceptin
The wonder drug Herceptin is the primary treatment for HER2-positive breast cancer. The 25 -30 % of breast cancer patients with this class of tumor do not all respond to Herceptin.
However, better treatment options can be determined if breast cancer patients can be evaluated of how they would respond to Herceptin.
Research teams from Harvard and Yale […]
Recent Comments